Patents by Inventor José Van Der Heyden

José Van Der Heyden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMMUNE-CELL TARGETED BISPECIFIC CHIMERIC PROTEINS AND USES THEREOF
    Publication number: 20220226441
    Abstract: The present invention relates, in part, to targeted chimeric proteins with beneficial therapeutic effects, including, for example, effects mediated by chimeric proteins which comprise modified signaling agents two or more targeting moieties. Methods of treatment and pharmaceutical compositions comprising the chimeric proteins are also provided. The present invention finds use in the treatment of various disease and disorders.
    Type: Application
    Filed: December 30, 2021
    Publication date: July 21, 2022
    Inventors: Jan TAVERNIER, Jose VAN DER HEYDEN, Genevieve GARCIN, Gilles UZE, Yann BORDAT
  • CD20 BINDING SINGLE DOMAIN ANTIBODIES
    Publication number: 20220185904
    Abstract: The present application relates, in part, to agents that bind CD20 and their use as therapeutic agents. The present application further relates to pharmaceutical compositions comprising the CD20 binding agents and their use in the treatment of various diseases.
    Type: Application
    Filed: December 21, 2021
    Publication date: June 16, 2022
    Inventors: Jan TAVERNIER, Anje CAUWELS, José VAN DER HEYDEN
  • Immune-cell targeted bispecific chimeric proteins and uses thereof
    Patent number: 11246911
    Abstract: The present invention relates, in part, to targeted chimeric proteins with beneficial therapeutic effects, including, for example, effects mediated by chimeric proteins which comprise modified signaling agents two or more targeting moieties. Methods of treatment and pharmaceutical compositions comprising the chimeric proteins are also provided. The present invention finds use in the treatment of various disease and disorders.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: February 15, 2022
    Assignees: VIB VZW, Centre National de la Recherche Scientifique, Univeriteit Gent, Universite de Montpellier
    Inventors: Jan Tavernier, Jose Van Der Heyden, Genevieve Garcin, Gilles Uze, Yann Bordat
  • CD20 binding single domain antibodies
    Patent number: 11248057
    Abstract: The present application relates, in part, to agents that bind CD20 and their use as therapeutic agents. The present application further relates to pharmaceutical compositions comprising the CD20 binding agents and their use in the treatment of various diseases.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: February 15, 2022
    Assignees: VIB VZW, Universiteit Gent
    Inventors: Jan Tavernier, Anje Cauwels, José Van Der Heyden
  • IMMUNE-CELL TARGETED BISPECIFIC CHIMERIC PROTEINS AND USES THEREOF
    Publication number: 20190351021
    Abstract: The present invention relates, in part, to targeted chimeric proteins with beneficial therapeutic effects, including, for example, effects mediated by chimeric proteins which comprise modified signaling agents two or more targeting moieties. Methods of treatment and pharmaceutical compositions comprising the chimeric proteins are also provided. The present invention finds use in the treatment of various disease and disorders.
    Type: Application
    Filed: February 6, 2018
    Publication date: November 21, 2019
    Inventors: Jan TAVERNIER, Jose VAN DER HEYDEN, Genevieve GARCIN, Gilles UZE, Yann BORDAT
  • CD20 BINDING SINGLE DOMAIN ANTIBODIES
    Publication number: 20190092871
    Abstract: The present application relates, in part, to agents that bind CD20 and their use as therapeutic agents. The present application further relates to pharmaceutical compositions comprising the CD20 binding agents and their use in the treatment of various diseases.
    Type: Application
    Filed: March 7, 2017
    Publication date: March 28, 2019
    Inventors: Jan TAVERNIER, Anje CAUWELS, José VAN DER HEYDEN
  • CD20 BINDING AGENTS AND USES THEREOF
    Publication number: 20190077871
    Abstract: The present invention relates to radiolabeled binding agents (e.g. antibodies, such as, without limitation, single-domain antibodies) which bind CD20 and their use as diagnostic, prognostic, predictive and therapeutic agents.
    Type: Application
    Filed: March 6, 2017
    Publication date: March 14, 2019
    Inventors: Jan Tavernier, José Van Der Heyden, Nick Devoogdt, Matthias D'Huyvetter, Ahmet Krasniqi
  • Chimeric interleukin 5-receptor/immunoglobulin polypeptides
    Patent number: 5712121
    Abstract: Chimeric polypeptides encoded by a DNA sequence having a first DNA subsequence coding for a fragment of at least one of the .alpha.-and/or .beta.-chain of the human interleukin-5 receptor, and a second DNA subsequence coding for the constant domains of a heavy--or a light-chain of a human immunoglobulin, or a fragment thereof are useful in treating illnesses with demonstrated eosinophilia.
    Type: Grant
    Filed: April 13, 1995
    Date of Patent: January 27, 1998
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Rene Devos, Walter Fiers, Jose van der Heyden, Geert Plaetinck, Jan Tavernier
  • Chimeric interleukin 5-receptor/immunoglobulin polypeptides
    Patent number: 5668256
    Abstract: Chimeric polypeptides encoded by a DNA sequence having a first DNA subsequence coding for a fragment of at least one of the .alpha.- and/or .beta.-chain of the human interleukin-5 receptor, and a second DNA subsequence coding for the constant domains of a heavy- or a light-chain of a human immunoglobulin, or a fragment thereof are useful in treating illnesses with demonstrated eosinophilia.
    Type: Grant
    Filed: April 13, 1995
    Date of Patent: September 16, 1997
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Rene Devos, Walter Fiers, Jose van der Heyden, Geert Plaetinck, Jan Tavernier
  • DNA encoding chimeric polypeptides comprising the interleukin-5 receptor .alpha.-chain fused to immunoglobulin heavy chain constant regions
    Patent number: 5455337
    Abstract: Chimeric polypeptides encoded by a DNA sequence having a first DNA subsequence coding for a fragment of at least one of the .alpha.- and/or .beta.-chain of the human interleukin-5 receptor, and a second DNA subsequence coding for the constant domains of a heavy- or a light-chain of a human immunoglobulin, or a fragment thereof are useful in treating illnesses with demonstrated eosinophilia.
    Type: Grant
    Filed: September 16, 1992
    Date of Patent: October 3, 1995
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Rene Devos, Walter Fiers, Jose van der Heyden, Geert Plaetinck, Jan Tavernier